
{
  "Company Overview": {
    "Name": "Windlas Biotech Ltd",
    "Sector": "Pharmaceuticals",
    "Industry": "Pharmaceuticals - Indian - Formulations",
    "Business Description": "A leading domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). The company manufactures both solid and liquid pharmaceutical dosage forms and provides a comprehensive range of CDMO services ranging from product discovery, product development, and commercial manufacturing of generic products, including complex generics.",
    "Market Position": "Amongst the top five players in the domestic pharmaceutical formulations, contract development, and manufacturing organization (CDMO) industry in India, in terms of revenues."
  },
  "Financial Metrics": {
    "Market Cap": "₹ 2,156 Cr.",
    "Current Price": "₹ 1,032",
    "High / Low": "₹ 1,198 / 423",
    "Stock P/E": 35.2,
    "Book Value": "₹ 225",
    "Dividend Yield": "0.53 %",
    "ROCE": "18.2 %",
    "ROE": "13.7 %",
    "Face Value": "₹ 5.00",
    "Debt-to-Equity Ratio": null //Not explicitly provided, needs further extraction from Balance Sheet data.

  },
  "Performance Trends": {
    "Quarterly Results": {
      "Sales": [115, 118, 122, 120, 133, 120, 141, 145, 153, 162, 171, 175, 187],
      "Expenses": [102, 105, 108, 106, 117, 106, 124, 128, 134, 142, 149, 154, 164],
      "Operating Profit": [13, 13, 14, 14, 16, 14, 16, 17, 19, 20, 22, 21, 23],
      "OPM %": ["11%", "11%", "11%", "12%", "12%", "12%", "12%", "12%", "12%", "13%", "13%", "12%", "12%"],
      "Other Income": [1, 2, 3, 3, 3, 2, 2, 3, 3, 3, 4, 4, 5],
      "Interest": [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1],
      "Depreciation": [3, 3, 3, 3, 3, 3, 4, 3, 3, 3, 4, 6, 6],
      "Profit before tax": [11, 11, 14, 14, 16, 13, 15, 16, 18, 20, 23, 18, 20],
      "Tax %": ["24%", "28%", "-8%", "28%", "22%", "28%", "24%", "26%", "23%", "24%", "25%", "26%", "23%"],
      "Net Profit": [8, 8, 15, 10, 12, 9, 11, 12, 14, 15, 17, 13, 16],
      "EPS in Rs": [3.81, 3.81, 6.79, 4.50, 5.59, 4.26, 5.38, 5.80, 6.75, 7.26, 8.17, 6.45, 7.49]
    },
    "Annual Results": {
      "Sales": [352, 307, 329, 428, 466, 513, 631, 696],
      "Expenses": [313, 270, 295, 373, 414, 453, 553, 609],
      "Operating Profit": [39, 38, 34, 55, 52, 60, 78, 86],
      "OPM %": ["11%", "12%", "10%", "13%", "11%", "12%", "12%", "12%"],
      "Other Income": [4, 54, 2, -19, 7, 10, 13, 17],
      "Interest": [6, 5, 3, 1, 1, 1, 1, 2],
      "Depreciation": [17, 11, 9, 13, 12, 12, 13, 20],
      "Profit before tax": [20, 76, 25, 22, 46, 57, 77, 81],
      "Tax %": ["44%", "16%", "34%", "28%", "16%", "25%", "25%", null],
      "Net Profit": [11, 64, 16, 16, 38, 43, 58, 61],
      "EPS in Rs": [20.04, 99.55, 25.28, 24.69, 17.48, 20.04, 27.98, 29.37]
    },
    "Growth Rates": {
      "Compounded Sales Growth": {
        "10 Years": null,
        "5 Years": "15%",
        "3 Years": "14%",
        "TTM": "25%"
      },
      "Compounded Profit Growth": {
        "10 Years": null,
        "5 Years": "21%",
        "3 Years": "23%",
        "TTM": "31%"
      },
      "Stock Price CAGR": {
        "10 Years": null,
        "5 Years": null,
        "3 Years": "57%",
        "1 Year": "141%"
      }
    },
    "Return on Equity": {
      "10 Years": null,
      "5 Years": "12%",
      "3 Years": "12%",
      "Last Year": "14%"
    }
  },
  "Ratios": {
    "Debtor Days": [69, 73, 71, 68, 87, 83, 79],
    "Inventory Days": [54, 36, 85, 55, 71, 84, 57],
    "Days Payable": [130, 110, 143, 53, 76, 98, 121],
    "Cash Conversion Cycle": [-7, -1, 13, 70, 81, 69, 15],
    "Working Capital Days": [-5, 9, 26, 66, 90, 73, 33],
    "ROCE %": ["15%", "12%", "19%", "15%", "14%", "18%", null]
  },
  "Peer Comparison": {
    "Peers": [
      {"Name": "Torrent Pharma.", "CMP": 3437.00, "P/E": 66.84, "Mar Cap": 116318.47, "Div Yld": 0.81, "NP Qtr": 453.00, "Qtr Profit Var": 17.36, "Sales Qtr": 2889.00, "Qtr Sales Var": 8.61, "ROCE": 23.16},
      {"Name": "Ajanta Pharma", "CMP": 2866.45, "P/E": 40.92, "Mar Cap": 35805.43, "Div Yld": 1.26, "NP Qtr": 216.48, "Qtr Profit Var": 10.84, "Sales Qtr": 1186.64, "Qtr Sales Var": 15.38, "ROCE": 31.60},
      {"Name": "Gland Pharma", "CMP": 1772.30, "P/E": 42.22, "Mar Cap": 29198.95, "Div Yld": 1.13, "NP Qtr": 163.53, "Qtr Profit Var": -15.74, "Sales Qtr": 1405.83, "Qtr Sales Var": 2.36, "ROCE": 13.58},
      {"Name": "ERIS Lifescience", "CMP": 1380.30, "P/E": 54.12, "Mar Cap": 18789.92, "Div Yld": 0.00, "NP Qtr": 96.35, "Qtr Profit Var": -25.12, "Sales Qtr": 741.17, "Qtr Sales Var": 46.68, "ROCE": 11.27},
      {"Name": "Caplin Point Lab", "CMP": 2311.45, "P/E": 35.62, "Mar Cap": 17569.72, "Div Yld": 0.22, "NP Qtr": 130.81, "Qtr Profit Var": 13.87, "Sales Qtr": 483.10, "Qtr Sales Var": 17.81, "ROCE": 26.46},
      {"Name": "Sai Life", "CMP": 703.65, "P/E": 176.75, "Mar Cap": 14635.18, "Div Yld": 0.00, "NP Qtr": 28.01, "Qtr Profit Var": 675.29, "Sales Qtr": 5.13, "Qtr Sales Var": 10.57, "ROCE": null},
      {"Name": "Marksans Pharma", "CMP": 304.90, "P/E": 39.92, "Mar Cap": 13816.96, "Div Yld": 0.20, "NP Qtr": 97.76, "Qtr Profit Var": 15.80, "Sales Qtr": 641.92, "Qtr Sales Var": 20.83, "ROCE": 20.61},
      {"Name": "Windlas Biotech", "CMP": 1031.55, "P/E": 35.21, "Mar Cap": 2155.97, "Div Yld": 0.53, "NP Qtr": 15.66, "Qtr Profit Var": 11.62, "Sales Qtr": 187.00, "Qtr Sales Var": 22.49, "ROCE": 18.17}
    ],
    "Median": {
      "CMP": 372.42,
      "P/E": 36.33,
      "Mar Cap": 520.58,
      "Div Yld": 0.14,
      "NP Qtr": 7.85,
      "Qtr Profit Var": 10.84,
      "Sales Qtr": 69.66,
      "Qtr Sales Var": 10.68,
      "ROCE": 13.41
    }
  },
  "Other Insights": {
    "Pros": [
      "Company is almost debt free.",
      "Company has delivered good profit growth of 21.2% CAGR over last 5 years",
      "Company has been maintaining a healthy dividend payout of 19.8%",
      "Company's working capital requirements have reduced from 65.3 days to 32.8 days"
    ],
    "Cons": [
      "Company has a low return on equity of 12.3% over last 3 years."
    ],
    "Disclaimer": "The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.",
    "Shareholding Pattern Notes": "* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards. Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes. Click on the line-items to see the names of individual entities."
  },
  "BalanceSheet": {
    "Equity Capital": [6, 6, 6, 6, 11, 10, 10, 10],
    "Reserves": [119, 187, 203, 193, 384, 392, 440, 461],
    "Borrowings": [57, 32, 29, 32, 7, 5, 4, 19],
    "Other Liabilities": [107, 73, 100, 65, 90, 122, 173, 257],
    "Total Liabilities": [290, 298, 338, 296, 491, 529, 626, 747],
    "Fixed Assets": [86, 64, 70, 96, 91, 109, 179, 188],
    "CWIP": [53, 5, 0, 0, 8, 15, 6, 31],
    "Investments": [23, 122, 116, 23, 65, 107, 173, 182],
    "Other Assets": [128, 107, 152, 177, 327, 298, 268, 346],
    "Total Assets": [290, 298, 338, 296, 491, 529, 626, 747]
  },
  "CashFlow": {
    "Cash from Operating Activity": [35, 19, 25, 11, 9, 61, 109],
    "Cash from Investing Activity": [-11, -7, -14, -20, -155, -14, -92],
    "Cash from Financing Activity": [-26, -6, -5, 1, 130, -44, -15],
    "Net Cash Flow": [-2, 6, 5, -8, -15, 3, 2]
  },
  "Shareholding Pattern": {
    "Quarterly": {
      "Promoters": [59.95, 59.95, 59.95, 59.95, 60.75, 62.37, 62.82, 62.82, 62.82, 62.82, 62.51, 62.51],
      "FIIs": [3.77, 3.40, 3.21, 2.19, 1.45, 1.32, 0.80, 0.80, 1.35, 1.18, 1.59, 2.00],
      "DIIs": [11.30, 9.83, 12.23, 11.14, 12.20, 11.61, 11.53, 11.52, 11.71, 11.82, 10.35, 9.58],
      "Public": [24.99, 26.82, 24.62, 26.71, 25.59, 24.68, 24.84, 24.85, 24.11, 24.19, 25.55, 25.91]
    },
    "Yearly": {
      "Promoters": [59.95, 62.37, 62.82, 62.51],
      "FIIs": [3.40, 1.32, 1.18, 2.00],
      "DIIs": [9.83, 11.61, 11.82, 9.58],
      "Public": [26.82, 24.68, 24.19, 25.91]
    },
    "No. of Shareholders": [99271, 92115, 88746, 86801, 82690, 79233, 75470, 68798, 61900, 51277, 45824, 45706]
  }
}
